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Introduction
The clinical interpretation of the presence of a non-tuberculous 
mycobacterium (NTM) lung infection in respiratory samples 
is challenging, unlike tuberculosis (TB) the isolation of an 
NTM in a respiratory culture does not automatically imply 
pathogenicity. Currently, NTM consist of more than 150 species, 
and they are globally ubiquitous in both natural and man-made 
environments [1]. In certain scenarios, the microorganism could 
be a transient colonizer or even a contaminant generated at 
the time of sample collection or processing in the laboratory. 
The diagnosis of disease is based on clinical, radiological and 
microbiological criteria [2].
NTM are ubiquitous microorganisms with nearly 100 different 
species found in soil and water. The fatty-acid and wax-rich 
impermeable cell wall of the mycobacteria can form biofilm that 
allow for adherence to solid substrates such as pipes and leaves, 
allowing the organism to persist despite treatment with common 
disinfectants, most notably chlorine based disinfectants [1, 3]. 
According to Nishiuchi, Iwamoto and Maruyama, the formation 
of aerosols containing NTM arising from shower water, soil, and 
pool water implies that these niches can be infection sources. 
Furthermore, genotyping has shown that clinical isolates are 
identical to environmental ones from household tap water, 
bathrooms, potting soil, and garden soil [4]. There is no 
evidence of person to person or zoonotic transmission despite 
that mycobacteria can cause infection in both humans, livestock 
and wildlife. Mycobacterium avium Complex (MAC) is the most 
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common NTM cause of pulmonary disease worldwide [5].
It is difficult to compare the incidence and prevalence of 
NTM diseases across geographic areas. Because reporting 
NTM disease to public health authorities is not required in 
most countries, studies of the incidence and prevalence of 
NTM disease are performed differently in different countries. 
To compare reports regarding changes in the incidence and 
prevalence of NTM disease over time in a limited geographic 
area, one must compare reports that used the same methods. 
Many epidemiological reports and reviews have shown that 
NTM disease have been increasing since the 1950s [1,6].
The clinical significance of NTM isolation is not always clear 
and it is difficult to assess the incidence or prevalence of 
NTM disease due to several factors, notably its difficulty in 
differentiation from colonization. Although the detection 
of NTM colonies has been increasing since the 1950s [6] it is 
unclear why NTM disease have been increasing in humans. 
There are several potential contributing factors, such as, (i) an 
increase of mycobacterial infection sources in the environment, 
(ii) an increase in susceptible individuals, such as those Human 
Immunodeficiency Virus (HIV) positive, (iii) improvements in 
detection methods and laboratory equipment sensitivities (iv) 
an increasing life expectancy of those with chronic structural 
pulmonary disease (v) an increased awareness of NTM diseases 
[1,7].
In many countries, especially those in high-burden areas for TB, 
the diagnosis of TB is mainly based on the detection of acid-fast 
bacilli in a sputum smear, as well as on their symptoms and the 
results of a chest X-ray [1]. Pulmonary diseases caused by NTM 
could be presumptively treated as pulmonary tuberculosis (TB) 
as the microbiologic smear of the sputum does not distinguish 
NTM from TB, and the clinical manifestations are similar. In 
Latin America the prevalence of NTM is estimated to be much 
lower than that of TB. The incidence of tuberculosis in Argentina 
is of 23,91/ 100,000 inhabitants with wide regional variations. 
In the province of Buenos Aires, it is 30,27/100,000 inhabitants. 
There are differences in the relative abundances of mycobacterial 
species that cause NTM diseases across geographic areas, the 
NTM distribution is most notably associated with variants 
in environmental factors such as, soil and water distribution 
systems [1,7]. Pulmonary diseases due to NTM  in HIV-negative 
patients are rarely described in the literature [8]. The objective 
of this study was to define the most frequent species of NTM 
causing pulmonary disease in HIV-negative patients in the city 
of Buenos Aires, Argentina. 
Materials and Methods
A retrospective review of all the respiratory cultures positive 
for NTM in the Bacteriology Laboratory of Posadas Hospital 
between January 2010 and December 2015 was performed. 
Posadas Hospital is a high complexity hospital with 500 
admission beds and a service area covering a population of 
approximately 4,400,000. IRB approval was obtained for this 
study.
Patients older than 15 years old that fulfilled the ATS/IDSA 
diagnostic criteria for pulmonary disease due to NTM were 
included in the study [2]. All patients in the study were screened 
for HIV and we excluded those who presented with positive HIV 
serology. 
The method utilized to perform the cultures was the BACTEC 
MGIT (fluorescence) in addition to solid culture media 
(Lowenstein Jensen). Lateral flow immunoassay (LFA) were 
performed on positive cultures to differentiate NTM from TB.
The following variables were analyzed: age, sex, NTM species, 
and clinical and radiological characteristics. For the categorical 
variables, we used percentages as frequency measurements. 
The continuous variables were expressed as mean or median 
depending on the sample distribution.  Statistical analysis was 
performed using the computing environment R version 3.4.3 
software [9]. 
Results
From a total of 1205 positive cultures for mycobacteria, 113 
(9.3%) correspond to NTM. 31 patients that fulfilled the 
inclusion criteria were included in the analysis. M. kansasii was 
isolated in 21 patients (67.7%), M. Avium Complex (MAC) was 
isolated in 6 patients (19.3%), M. fortuitum was isolated in 2 
patients (6.4%), M. abscessus was isolated in one patient (3.2%) 
and M. chelonae was isolated in one patient as well (3.2%).
Culture samples were obtained from bronchoalveolar lavage 
(BAL) and/or bronchial lavage in 21 patients (67.7%) and from 
sputum in 10 patients (32.3 %). The mean age was 50 years at 
the time of the diagnosis (SD ± 17.2); and 19 patients (61.3%) 
were males.
In our series, 17 patients (55%) had some predisposing factor for 
NTM disease. Ten patients (32.2%) had a previous pulmonary 
disease: (a) radiologic sequela of TB was noted in 3 patients, 
(b) Chronic Obstructive Pulmonary Disease (COPD) was 
present in 2 patients, (c) pulmonary carcinoma was present 
in another 2 patients, (d) asbestosis in 1 patient, (e) diffuse 
interstitial pulmonary disease associated with Rheumatoid 
arthritis in 1 patient and (f) cystic fibrosis were noted in 1 
patient. Eleven patients (35%) had a history of smoking. We 
found non-pulmonary comorbidities in four patients (12.9%): 
(a) rheumatoid arthritis, (b) multiple sclerosis (MS), (c) Acute 
myeloid leukemia (AML), (d) diabetes mellitus combined 
with hemolytic anemia. Three of these patients were receiving 
immunosuppressant. Four patients were older than 65 years 
without evidence of any comorbidities. (Table 1)
Table 1 Patient characteristics in Posadas Hospital Buenos Aires, 
Argentina (n=31)











Refractory Anemia (RA) 1(3.2)
Hemolytic anemia and Diabetes                                   1(3.2)
Multiple Sclerosis (MS) 1(3.2)
Acute myeloid leukemia (AML) 1(3.2)
Pulmonary comorbidities
Chronic obstructive pulmonary disease (COPD) 2(6.4)




Bronchiectasis                2(6.4)
Cavitary infiltrate 17 (55)
Smoking 11 (35.5)
Threatening hemoptysis 2 (6.4)
The most frequent radiographic finding was pulmonary 
cavitation, observed in 17 patients (55%). This finding was most 
commonly associated with M. kansasii. Bronchiectasis was 
noted in 2 patients, one of which had underlying cystic fibrosis. 
(Table 1)
Three deaths were noted in the study population. Two deaths 
were related to NTM disease and one was due to acute myeloid 
leukemia. Two patients presented with fulminant hemoptysis 
which resulting in death in one of the patients. All the patients 
received treatment according to the American Thoracic Society 
(ATS) guidelines [1].
Discussion 
The majority of pulmonary disease due to NTM is caused by 
slow-growing mycobacteria. The most commonly isolated 
species is MAC followed by M. kansasii. Amongst the rapid-
growing mycobacteria, M. abscessus was the most commonly 
isolated [2]. In our series, the most frequent isolated species 
was M. kansasii, contrary to what has been previously described 
in the literature. However, in Argentina and South America 
in general, data on NTM prevalence is variable. Barnes et 
al. described 75% of NTM isolates in pulmonary and extra 
pulmonary samples as MAC and only 3% as M. kansasii in a 
study including immunocompetent and immunocompromised 
patients, in Buenos Aires [9]. Imperiale et al. described MAC 
as the most frequently isolated NTM (32.2% of isolates) in 
pulmonary and extra-pulmonary infections, with M. kansasii in 
fourth place (8% of isolates) in a study which also included HIV 
patients [11]. Mello et al. conducted a study in Brazil to identify 
clinical and therapeutic features of pulmonary nontuberculous 
mycobacterial disease which included patients with AIDS. 
They found that M. kansasii was the most frequently isolated 
organism (33.9%) and MAC the second one in frequency 
(30.4%) [12].
The significant geographic variability in the distribution of M. 
kansasii has also been observed in other areas of the world with 
a high prevalence of pulmonary disease caused by this NTM in 
western Europe, Switzerland, and the United Kingdom [8]. In 
many countries, the most frequently reported mycobacterial 
species is MAC. In Japan and Oregon, USA, MAC has been 
reported to account for 88.8% of all cases of NTM diseases. 
In Eastern Asia, MAC accounts for 68% of all cases of NTM 
diseases. MAC was isolated more frequently in Northern Europe 
(44% of all mycobacteria) than in Southern Europe (31%). MAC 
was the most common species complex (64–85% of cases) 
in North America, followed in most studies by M. abscessus/
chelonae (3–13%), M. xenopi (1–23%), M. fortuitum (<1–8%), 
and M. kansasii (<1–6%). In Central and South America, MAC 
was generally most common, and M. kansasii was also reported 
frequently [1,8].
The transmission of MAC and other non-tuberculous 
mycobacteria organisms are likely to be linked with human 
activities. Global human mobility and trade may promote 
the global transmission of MAC via fomites [1]. Climatic and 
ecological factors (water, biofilm, residential soil and dust), as 
well as the prevalence of comorbidities such as HIV infection, 
likely have an impact on the prevalence of different NTM 
species in each region. Bonnet et al. described water sources, 
particularly well water, as an important reservoir for NTM 
infection, in Cambodia [7].
The best-defined risk factors NTM infection are advanced age, 
immunosuppression (including HIV infection), and  pulmonary 
disease (COPD, bronchiectasis, sequelae of previous TB, 
cystic fibrosis, etc.) [7,13,14] Anti-TNF-α agents (infliximab, 
etanercept, adalimumab), methotrexate and corticosteroids 
use also constitute risk factors for NTM disease. Low body 
mass index (BMI), skeletal abnormalities and gastroesophageal 
reflux have also been described as predisposing factors to NTM 
pathogenicity [15]. Children and teenagers rarely develop NTM 
disease. in the absence of underlying cystic fibrosis. In our study, 
the average age was 50 years old, less than the one described in 
the studies conducted in Europe or the USA [8].
 
Okoi et al. performed a systematic review of NTM isolated in 
respiratory samples in sub-Saharan Africa. In this review, the 
average age was 35 years old, likely related to the high prevalence 
rate of TB and a high rate of HIV coinfection in the region [16]. 
The clinical interpretation of the presence of NTM in respiratory 
cultures is problematic, as, unlike TB, the isolation of NTM in 
a respiratory sample does not imply pathogenicity. In certain 
situations, the microorganisms can be a transient colonizer 
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Figure 1 Substantial numbers of non-tuberculous mycobacteria (NTM) disease 
patients have been found among suspected tuberculosis (TB) and chronic TB 
patients worldwide [1].
or contaminant. The diagnosis of the disease is based on 
clinical, radiological and microbiological criteria [2]. In several 
countries, such as Argentina, NTM disease is non-reportable 
and therefore its incidence and prevalence are unknown. The 
current available epidemiologic data on NTM infections in 
Argentina is from a single institution, described in a study 
by Barnes et al. and may not be representative of the entire 
country or region [9]. Many developing countries, where TB is 
presumed to be more prevalent than NTM (3.4–39%) (Figure 
1) [1]. These TB prevalent countries follow their own established 
guidelines for the management of positive acid-fast bacilli 
cultures in a sputum smear, as well as on their symptoms and if 
available the results of a chest X-ray. Their treatment guidelines 
typically favor empiric therapy for TB and reserve more specific 
organism determination for certain clinical situations, such as 
suspected drug-resistant TB, TB treatment failures, children, 
immunocompromised patients, mycobacteriosis retreatment, 
health workers, prisoners, extra pulmonary disease, diabetes, 
immigrants from areas of high multidrug resistant tuberculosis 
rate and positive bronchoalveolar lavage and bronchial lavage 
samples. However, NTM disease patients are not cured by 
the 6-month anti-TB treatment and they are then potentially 
considered to have chronic or multidrug resistant TB. This 
then results in NTM patients who do not receive appropriate 
treatment for their NTM disease, annual TB reports that contain 
errors; and unnecessary expenses for TB treatments. Thus, a 
reliable, low-cost mycobacterial diagnostic method that results 
in species-level identification is urgently required [1].
The small sample size our study is a limitations, as well as the 
lack of surveillance for pulmonary NTM hinders the ability 
to test these hypotheses and ultimately prevent infection. In 
addition, our study samples were all collected at the same 
institution and may not be representative of other national or 
regional data. Furthermore, cultures were not obtained from all 
the samples, and environmental and occupational variables was 
not collected. One of the strengths of our study was that only 
patients who meet disease criteria were included and also HIV-
positive patients were excluded allowing for an estimation of the 
prevalence of NTM disease in an immunocompetent population.
There has been a global improvement in the ability to 
recognize NTM as human pathogens. Technological advances 
in laboratory methods have, in addition, allowed faster and 
more accurate identification of different NTM species and their 
antimicrobial susceptibilities. These factors have contributed 
to a more tailored approach to management, in alignment with 
established international guidelines for treatment of specific 
NTM infection.
    
In conclusion, our study indicates that M. kansasii is the 
primary etiology of NTM pulmonary disease in HIV-negative 
patients in our service area in Buenos Aires, Argentina. 
This finding supports the consideration that patients with 
symptoms compatible with pulmonary tuberculosis should 
also be evaluated for NTM with appropriate acid- fast bacilli 
cultures, as treatment regimens differ vastly according to the 
specific pathogen isolated, although clinical and radiographic 
presentations may have overlapping features. The possibility 
of M. kansasii pulmonary disease or other NTM should be 
considered in patients treated empirically for TB without 
appropriate clinical response. 
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